Upregulated miR-410 is linked to poor prognosis in colorectal cancer. Issue 3 (2nd July 2020)

• Record Type: Journal Article
• Authors: Abedi, P; Bayat, A; Ghasemzadeh, S; Raad, M; Pashaiefar, H; Ahmadvand, M
• Is Part Of: British journal of biomedical science. Volume 77:Issue 3(2020)
• Page Start: 118
• Page End: 122
• Publication Date: 2020-07-02
• Subjects: miR-410 -- Colorectal cancer -- RT-qPCR -- prognosis -- overall survival -- clinicopathological characteristics; Medical sciences -- Periodicals; Medical technology -- Periodicals; Biological Science Disciplines; Clinical Laboratory Techniques; Medical Laboratory Science; Anatomie pathologique; Medical sciences; Medical technology; Klinische chemie; Laboratoriumonderzoek; Periodicals; Periodicals; 616.0756; 610.07 M489L
• DOI: 10.1080/09674845.2020.1731050
• Languages: English
• ISSNs: 0967-4845

Abstract

ABSTRACT: Background: Although miR-410 acts as a cancer inducer in colorectal cancer, there is limited data on the clinical implications of miR-410 expression levels in patients. We hypothesized a link between miR-410 expression and its potential clinical values in patients with colorectal cancer. Material and methods: 120 colorectal cancer tissue specimens and 120 adjacent non-tumour tissues were obtained. Quantification of miR-410 expression levels was determined by, quantitative RT-PCR. Expression was analysed by clinical features. Results: miR-410 was up-regulated in malignant tissues compared with corresponding normal tissues ( P < 0.01), with TNM stage and lymph node metastasis ( P = 0.03, P = 0.004, respectively), and with worse overall survival ( P = 0.002). Multivariate survival analysis identified it as an independent risk factor for outcome ( P = 0.021, HR = 2.19; 95% CI = 1.12–4.25). Conclusion: Compared to normal non-cancerous tissues, miR-410 was overexpressed in tumour tissues and is independently associated with the unfavourable outcome. Levels of MiR-410 might a useful laboratory tool in managing and predicting the prognosis of colorectal cancer.